Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Pacira Pharmaceuticals, Inc | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This is a prospective, quasi-experimental, cohort study comparing patients treated with one of two postoperative pain management protocols. The two protocols assessed will be the current standard of care protocol for Anterior Cruciate Ligament Reconstruction (ACLR) postoperative pain control utilized by Dr. Matthew Varacallo and then an opioid avoidance protocol that is planned to be implemented on the Spring of 2024. The study is voluntary, however all patients will be treated with either of the two protocols depending on their date of surgery. This study will include patients aged 15 years and older who consent to the participation in the study. Patients will be identified utilizing the operative surgeon's appointment calendar and will be screened and offered inclusion in the study if applicable at their pre-operative visit. Data will be collected via patient medication and pain diary, phone call, and clinician administration of standardized outcome questionnaires. Patients will be included in the standard of care group if ACLR is performed prior to the change in protocol in the Spring of 2024 or the opioid avoidance group if performed after the protocol change.
The primary objective of this study is to evaluate the effect of the opioid avoidance protocol on opioid use in milligrams of morphine equivalent (MME) from postoperative day (POD) 0 to 7 after ACLR compared to the current standard of care pain management protocol.
Secondary objectives are to:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard of Care | Treatment of pain as per standard of care. Patients will receive regional anesthesia blocks, acetaminophen, and as needed opioids; tramadol and oxycodone postoperatively for pain management. |
| |
| Opioid Avoidance | Preoperatively patients will receive cryoneurolysis of 5 sensory nerves that innervate the knee 7 to 21 days before surgery. Patients will receive perioperative NSAIDs and acetaminophen along with regional anesthesia. For postoperative pain control patients will receive scheduled acetaminophen and NSAIDs and may request opioids as needed. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Iovera | Device | Cryoneurolysis of 5 sensory nerves (Intermediate branch of the AFCN, Medial Femoral Cutaneous Nerve, Suprapatellar branch of the saphenous nerve, 2 branches of the infrapatellar branch of the saphenous nerve) causing Wallerian degeneration |
| Measure | Description | Time Frame |
|---|---|---|
| Opioid consumption from post-operative day 0 to 7 | Total use of opioids in milligrams of morphine equivalent from day 0 through day 7 | 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| Average daily pain score via numeric rating scale (NRS) | Average daily pain each day from POD0-7 | 7 Days |
| Average daily worst pain score via NRS | Average of highest pain scores daily |
Not provided
Inclusion Criteria:
Patients aged 15 years or older at screening.
Primary diagnosis of ACL injury as evidenced by MRI or similar imaging study and are scheduled to undergo ACLR with or without meniscal repair/meniscectomy
Non-pregnant patients with verbal confirmation that they are not planning to become pregnant during the study period.
i. Female subjects must have a confirmatory negative pregnancy test as part of the routine pre-operative laboratory testing ii. Subjects must endorse a plan to utilize contraceptives (condoms, hormonal birth control, IUD, etc.) for any sexual activity during the study period.
English speaking patients
Provision of informed consent with ability to adhere to the study visit schedule and complete all study assessments.
Exclusion Criteria:
Allergy, hypersensitivity, intolerance, or contraindication to any of the study medications
History of contralateral ACL repair within 1 year of screening
Multi-ligament injury requiring reconstruction
Inability to return to the study doctor's clinic for postoperative visits
Pregnant or trying to become pregnant
Breastfeeding
Have a severe chronic pain condition that in the opinion of the study doctor may impact post-surgical outcomes of analgesic and opioid usage (i.e., fibromyalgia, cancer, sickle cell disease)
Have a known contraindication to the iovera° device, including any of the following:
i. Cryoglobulinemia (presence of abnormal proteins in the blood that thicken in cold temperatures) ii. Paroxysmal cold hemoglobinuria (an autoimmune disorder where cold-reacting antibodies that attack and destroy red blood cells) iii. Cold urticaria (temporary itchy welts [hives] on skin exposed to cold temperatures) iv. Raynaud's disease (which causes some areas of the body, such as fingers and toes, to feel numb and cold in response to cold temperatures) v. Open and/or infected wounds at or near the study treatment site vi. Coagulopathy (problems with blood clotting)
Have poorly controlled mental illness that in the opinion of the study doctor may meaningfully impact study treatment outcomes, including any of the following:
i. Mood disorder (for example, major depression, bipolar) ii. Psychotic disorder (for example, schizophrenia)
Have a history, suspicion, or clinical manifestation of:
i. Alcohol abuse or dependence ii. Illicit drug use iii. Opioid abuse or dependence (greater than or equal to 40 mg morphine equivalent dose by mouth per day in the past 30 days)
Pregnant or planning to become pregnant during the study period
Not provided
Not provided
Not provided
Adolescents (15 years of age or older) or Adults undergoing primary ACL reconstruction with or without meniscal repair.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Penn Highlands Dubois | DuBois | Pennsylvania | 15801 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000070598 | Anterior Cruciate Ligament Injuries |
| D010149 | Pain, Postoperative |
| ID | Term |
|---|---|
| D007718 | Knee Injuries |
| D007869 | Leg Injuries |
| D014947 | Wounds and Injuries |
| D011183 | Postoperative Complications |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068579 | Celecoxib |
| D000082 | Acetaminophen |
| D010098 | Oxycodone |
| D014147 | Tramadol |
| D002045 | Bupivacaine |
| D002214 | Capsules |
| ID | Term |
|---|---|
| D000096926 | Benzenesulfonamides |
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
| Celecoxib | Drug | 200mg BID |
|
|
| Acetaminophen | Drug | 1000mg q8h |
|
|
| Oxycodone | Drug | As needed |
|
| Tramadol | Drug | As needed |
|
| Bupivacaine Hydrochloride | Drug | 20mL of 0.25% bupivacaine HCl adductor canal block and 15mL of 0.25% bupivacaine HCl (+/- 5mL of normal saline) iPACK |
|
| Acetaminophen 500Mg Cap | Drug | 500mg q6h prn |
|
| 7 days |
| Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain Subscale Score | Pain subscale of the KOOS questionnaire | Week 8 |
| Quality of Recovery-15 | QoR15 score on POD2 | Day 2 |
| Pittsburgh Rehabilitation Participation Scale Score | Ability to participate in physical therapy weekly | 8 weeks |
| KOOS symptom subscale score | Symptom subscale of the KOOS questionnaire | Week 8 |
| Quantity of opioid prescriptions utilized at day 30 and 60 | Number of opioid prescriptions filled by patient at day 30 and 60 | Day 30 and Day 60 |
| Opioid-free at day 7, day 30, and day 60 | Percentage of patients who did not utilize opioid prescriptions at 3 time points | Days 7, 30, and 60 |
| D010335 |
| Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D001555 |
| Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D011720 | Pyrazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D000083 | Acetanilides |
| D000813 | Anilides |
| D000814 | Aniline Compounds |
| D000588 | Amines |
| D003061 | Codeine |
| D009022 | Morphine Derivatives |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
| D003511 | Cyclohexanols |
| D000441 | Hexanols |
| D005233 | Fatty Alcohols |
| D000438 | Alcohols |
| D004123 | Dimethylamines |
| D008744 | Methylamines |
| D008055 | Lipids |
| D004304 | Dosage Forms |
| D004364 | Pharmaceutical Preparations |